Summit Therapeutics plc (SMMT) Social Stream



Summit Therapeutics plc (SMMT): $0.95

-0.05 (-4.68%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Summit Therapeutics Inc (SMMT) Price Targets From Analysts

Use the tables below to see what analysts covering Summit Therapeutics Inc think about its future price and what recommendations they have for investors and traders.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
NA 1 $NA $NA $NA $2.71 NA%

Price Target Last Issued NA NA, NA

The Trend in the Analyst Price Target


Over the past 32 weeks, SMMT's average price target has gone up $0.5.

Over the past 170 days, SMMT's average upside potential has been -33.91%.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2021-04-17 2 5 4 4.5 5.36 -16.04%
2021-06-05 2 5 4 4.5 8.00 -43.75%
2021-07-24 3 5 4 4.5 8.00 -43.75%
2021-08-01 3 5 4 4.5 7.33 -38.61%
2021-09-11 3 5 4 4.5 6.50 -30.77%

SMMT Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
3 0 0 1 0 0 1

The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for SMMT as an investment opportunity.

  • In terms of how Summit Therapeutics Inc fares relative to all US stocks, note that its number of analysts covering the stock is higher than practically none of that group.
  • Summit Therapeutics Inc's variance in analysts' estimates is lower than just about 100% of stocks in the small market cap category.
  • To contextualize these metrics, consider that out of stocks in the small market cap category, Summit Therapeutics Inc's average analyst price target is greater than practically none of them.
  • In terms of how Summit Therapeutics Inc fares relative to stocks in the small market cap category, note that its upside potential (average analyst target price relative to current price) is greater than practically none of that group.

In the Pharmaceutical Products industry, SLS, SLRX, and SLGL are the three stocks most similar to Summit Therapeutics Inc regarding the price target and analyst recommendation information presented here.

Is SMMT a Buy, Hold or Sell? See the POWR Ratings now!


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4507 seconds.